Crossmark

Low dose anti-thymocyte globulin with low dose posttransplant cyclophosphamide (low dose ATG/PTCy) can reduce the risk of graft-versus-host disease as compared with standard-dose anti-thymocyte globulin in haploidentical peripheral hematopoietic stem cell transplantation combined with unrelated cord blood

Crossref DOI link: https://doi.org/10.1038/s41409-020-01047-2

Published Online: 2020-09-01

Published Print: 2021-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Xiaoqian https://orcid.org/0000-0003-1888-4046
Yang, Jun

Cai, Yu https://orcid.org/0000-0001-8804-2616
Li, Su

Niu, Jiahua

Zhou, Kun

Jiang, Ying

Xu, Xiaowei

Shen, Chang

Huang, Chongmei

Qiu, Huiying

Wei, Daolin

Kang, Mei

Tong, Yin

Wei, Zheng https://orcid.org/0000-0003-1559-7148
Liu, Peng

Wan, Liping

Song, Xianmin https://orcid.org/0000-0003-0637-5324
License Information

Text and Data Mining valid from 2020-09-01

Version of Record valid from 2020-09-01
More Information

Article History

Received: 18 October 2019

Revised: 7 August 2020

Accepted: 25 August 2020

First Online: 1 September 2020

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below